News
NIH is issuing an Intramural Research Program (IRP) policy to promote access to IRP-supported inventions resulting in drugs, biologics, vaccines, or devices. As of June 1, 2025, organizations applying to NIH for certain commercial patent licenses will be required to submit Access Plans to NIH
Looking to work with the National Institutes of Health (NIH), the world’s largest biomedical research institution? The NIH Office of Technology Transfer has updated its "Business Opportunities at the NIH" guide for companies seeking new discoveries for commercialization, research & clinical
Chemotherapy is one of the most important treatments for colorectal cancer, especially those at late stages. Camptothecin (CPT) has demonstrated antitumor activity, but failed in clinical trials due to the low solubility and adverse side effects. In other words, CPT does not circulate well in the
The Technology Transfer Center (TTC) at the National Cancer Institute (NCI) is offering an exclusive Start-Up Evaluation Option License, called Start-Up 2.0, to qualified companies for term limited evaluation of certain early-stage vaccine, therapeutic, device, and diagnostic technologies stemming